BioCryst says Japan approves Orladeyo for pediatric HAE patients aged 2-11

BioCryst Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare has approved Orladeyo for pediatric patients aged 2 to under 12 with hereditary angioedema. This approval grants access to the first oral prophylactic option for this age group in Japan, following National Health Insurance pricing. OrphanPacific holds the marketing authorization.

BioCryst won Japanese MHLW marketing clearance for once-daily Orladeyo to prevent hereditary angioedema attacks in children aged 2 to <12. * Approval broadens Japan access to the first oral prophylactic option for this age group; launch follows National Health Insurance pricing. * OrphanPacific holds the Japan marketing authorization. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250701PRIMZONEFULLFEED9815310) on August 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)